No Evidence of Reye’s/Nonaspirin Salicylates Link - Procter & Gamble
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble will continue to support Reye's syndrome warnings for bismuth salicylates, provided that such warnings do not imply the ingredient increases risk of the disease
You may also be interested in...
Attapulgite, Polycarbophil Excluded From OTC Antidiarrheal Final Monograph
Activated attapulgite is reclassified from proposed Category I status to nonmonograph in the 1OTC Antidiarrheal Drug Products final monograph, published in the April 17 Federal Register
Bismuth Subsalicylate “Relieves Travelers’ Diarrhea” Claim Proposed by FDA
Relief of travelers' diarrhea would be included as an indication for bismuth subsalicylate products in the OTC antidiarrheal drug final monograph under a proposed rule published in the 1April 17 Federal Register
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC